Biological warfare defense vaccine research and development program: hearing before the Subcommitttee on National Security, Veterans Affairs, and International Relations of the Committee on Government Reform, House of Representatives, One Hundred Seventh Congress, first session, October 23, 2001, Volumen4
United States. Congress. House. Committee on Government Reform. Subcommittee on National Security, Veterans Affairs, and International Relations
U.S. Government Printing Office, 2002 - 129 páginas
Comentarios de la gente - Escribir un comentario
No encontramos ningún comentario en los lugares habituales.
Otras ediciones - Ver todas
able additional agents American anthrax vaccine antibiotics antigen approach approved areas attack believe better biological BioPort bioterrorism Chairman changes clinical committee companies concern continue currently deal Defense Department discuss disease drugs effective efficacy effort event facility Fauci fermenters filter funding going Government happen hearing human immune important industry inspect issue it's kind KUCINICH licensed look manufacturing Michigan million months October Office pharmaceutical Phase potential practices prepared President protection public health PUTNAM question Readiness reported require Research and Development response role safety SANDERS Secretary THOMPSON SHAYS smallpox studies Subcommittee sure talked testimony testing Thank there's things threat toxin trials trying understand we're
Página 30 - I will be happy to answer any questions which you or members of the Subcommittee may have.
Página 1 - The dogmas of the quiet past are inadequate to the stormy present. The occasion is piled high with difficulty, and we must rise with the occasion. As our case is new, so we must think anew and act anew. We must disenthrall ourselves, and then we shall save our country.
Página 22 - In some cases, new vaccines, antitoxins, or innovative drug treatments need to be developed, manufactured, and/or stocked. Moreover, we need to learn more about the pathogenesis and epidemiology of the infectious diseases which do not affect the US population currently. We have only limited knowledge about how artificial methods of dispersion may affect the infection rate, range of illness, and public health impact of these biological agents.
Página 70 - BEFORE THE SUBCOMMITTEE ON NATIONAL SECURITY, VETERANS AFFAIRS AND INTERNATIONAL RELATIONS, HOUSE COMMITTEE ON GOVERNMENT REFORM ON THE STANDARD PROCUREMENT SYSTEM FEBRUARY 7, 2002 Mr.
Página 75 - Products: Evidence needed to Demonstrate Efficacy of New Drugs for Use Against Lethal or Permanently Disabling Toxic Substances When Efficacy Studies in Human Ethically Cannot be Conducted'.
Página 100 - US states and 33 other nations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.
Página 71 - during the dependent's annual trip between the school and the member's duty station" and inserting "one time per fiscal year". SEC. 544. MODIFICATION OF PROHIBITION ON REQUIREMENT OF NONAVAILABILITY STATEMENT OR PREAUTHORIZATION. Section 721 of the Floyd D. Spence National Defense Authorization Act for Fiscal Year 2001 (Public Law 106-398; 114 Stat.
Página 12 - Department and other agencies to support and encourage research to address scientific issues related to bioterrorism. The capability to detect and counter bioterrorism depends to a significant degree on the state of relevant medical science.
Página 90 - Steele L. Prevalence and patterns of Gulf War Illness in Kansas veterans: association of symptoms with characteristics of person, place and time of military service.